Key Considerations
Generalizability: Despite major changes in various aspects of diagnosis and management of SAH, the results of this trial likely still apply to today's patients.
- Current management emphasizes identifying a ruptured aneurysm (CT angiography) and securing it early (<24 hours) to prevent re-rupture and re-bleed, the risk of which is 4% in the first 24h and 1.5%/day in the subsequent 2 weeks.
- In this trial, aneurysms were identified with DSA, often longer than 4 days after symptom onset. More concerning, patients waited an average of 11 days prior to surgical clipping of their aneurysm.
- Nimodipine was reported as equally beneficial in patients regardless of whether they underwent surgical clipping (versus no intervention).
- Notably, endovascular coiling is another modality now available to secure aneurysms, particularly for those with narrow necks found in the posterior cerebral circulation. This procedure was not available in the era when this trial was conducted.
- Endovascular coiling doesn't reduce delayed cerebral ischemia versus surgical clipping, & produces similar long-term functional outcomes; therefore, shouldn't impact effects of nimodipine.
- A sizable portion of patients enrolled in this trial (44%) did not have proven aneurysmal SAH at enrollment, & up to a quarter of all patients had non-aneurysmal SAH later diagnosed by angiography.
- The patients with non-aneurysmal SAH could not benefit from nimodipine, which likely led to the dilution of nimodipine's efficacy.
- This means that the true absolute reduction in poor outcomes with nimodipine is likely larger than reported, & the NNT is likely smaller than 8 (which is already impressive).
Additional logistic considerations for nimodipine:
- Nimodipine does not reduce cerebral vasospasm; this is not its underlying mechanism (which remains unknown)
- Because of this, nimodipine should ideally be continued in patients being treated for "clinical vasospasm," unless it is impairing the ability to achieve the blood pressure goals of hypertensive therapy ("triple-H therapy")
- Cost of a 21-day course: ~$3,100 (~$150/day)
- Many patients recover & are well enough to go home prior to the completion of the 21-day course of nimodipine. In these patients, risk of delayed cerebral ischemia is very low, particularly beyond 10 days of symptom onset, so nimodipine should be discontinued on discharge to avoid unnecessary cost (& difficulty in adhering to q4h dosing) to the patient.
Summary author: Ricky Turgeon BSc(Pharm), ACPR, PharmD
Summary date: Updated 14 July 2016